APVO Aptevo Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1671584 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY4.0%
TTM EPS YoY100.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-239.1%
ROA-125.9%
ROIC (approx.)-1,145.2%
Asset turnover—
Leverage & solvency
Liabilities / assets71.1%
Debt / equity0.00x
Current ratio1.50x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $14.54M | $14.38M |
| SG&A expense | $11.77M | $10.22M |
| Operating income | -$26.31M | -$24.60M |
| Pretax income | -$25.97M | -$24.13M |
| Income tax | $0 | — |
| Net income | -$25.97M | -$24.13M |
| EBITDA | -$26.07M | -$24.25M |
| EPS (basic) | -87.27 | -31,460.23 |
| EPS (diluted) | -87.27 | -31,460.23 |
| Weighted avg. shares (diluted) | 315,535 | 767 |
| Balance sheet | ||
| Cash & equivalents | $21.62M | $8.71M |
| Current assets | $23.08M | $10.66M |
| PP&E, net | $303,000 | $543,000 |
| Total assets | $27.19M | $15.59M |
| Current liabilities | $6.05M | $6.21M |
| Total liabilities | $9.81M | $10.84M |
| Shareholders' equity | $17.38M | $4.75M |
| Shares outstanding | 997,830 | 4,051 |
| Cash flow statement | ||
| Operating cash flow | -$25.59M | -$23.79M |
| Investing cash flow | $0 | $0 |
| Financing cash flow | $38.50M | $15.60M |
| Depreciation & amortization | $240,000 | $352,000 |
| Stock-based compensation | $96,000 | $1.07M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.